超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

桑迪亞Sundia MediTech
桑迪亞醫藥技術 （上海）有限責任公司，是由王曉川博士領銜的一批來自全球制藥行業的資深科研和管理精英于2004年創立的外包服務 (CRO) 公司，以上海為基地向全球制藥企業和生化公司提供優秀、高效的“一站式”新藥研發和生產服務。

2008年，桑迪亞公司以928％的財務增長率榮膺“德勤亞太地區高科技、高成長500強”第52名，“德勤中國高科技、高成長50強”第16名，并連續兩年被頂尖風險投資商評為“中國最有投資價值的50家公司”之一。同時，桑迪亞還榮獲了國家“高新技術企業”、“上海重點服務外包企業”、“浦東新區企業技術開發機構”、“2009中國100強成長型服務外包企業”等稱號。

桑迪亞的新藥研發外包服務幾乎涵蓋了新藥研發的大部分關鍵環節，具體包括：藥物分子設計，篩選，優化，合成，化學工藝研究與放大、化學分析測試、藥物制劑研究、分子診斷服務、藥理、藥效、藥代、安全性評價服務和符合美國cGMP規范的原料藥（High Potency API）和劑型的規模化生產等，集實驗室研發和cGMP生產于一體。

桑迪亞利用自行建立的新藥研發服務平臺，在過去5年多的時間內，已與來自國內外的80多家制藥公司進行了全面的研發合作，為合作伙伴發現了8個不同的候選藥物，其中有數個已進入臨床前研究階段，有一個為合作伙伴申報的國家“一類”創新藥物，獲得了中國國家食品藥品監督管理局（SFDA）的I期臨床批文。

2009年2月9日，張江集團和桑迪亞公司簽約共同建設“張江新藥孵化平臺”，在國內首次采用 IP+CRO+VC（即知識產權、研發外包服務、風險投資相結合）的全新產業化模式直接孵化新藥，這將打破國內新藥研發領域長期偏重于重復硬件建設而不出成果的困局, 能使我國的新藥研發快速進入到一個全新的階段。

成立7年來，桑迪亞公司規模不斷擴大，實驗室面積從最初的500平方米發展到如今的15,000平方米，科研、生產設施一流。目前，公司共有科研人員約600人，博士碩士比例約 90%，其中海歸高端人才比例約10% 。

Founded by a group of veterans from the US biopharmaceutical industry in 2004, Sundia MediTech Company Ltd. is now a leading Shanghai-based CRO company providing drug discovery and development services worldwide. In 2007, Sundia successfully merged with United PharmaTech and formed an alliance with HD Biosciences. With our technical expertise and excellent research facilities, we offer broad and integrated chemical synthesis (custom synthesis, library design and synthesis), medicinal chemistry (hit generation, lead optimization, and preclinical development), biological (early hit screening, assay development, in vitro and in vivo pharmacology, in vitro and in vivo DMPK), new technology platforms (molecular diagnostics and PBSDD and nanotechnology), and pharmaceutical development (process research and development, API manufacture, pre-formulation and formulation, analytical and QA/QC, CMC and regulatory submission) services.

Since its founding in 2004, the company's CRO service business has been growing at an amazing rate. It was consecutively named as one of the top 50 most valuable companies for investment in China in 2007 and 2008. In 2008, with its 928% revenue growth, Sundia ranked #52 in the Deloitte Technology Fast 500 Asia Pacific list and #16 in the Fast 50 China list. Our expansion through partnerships has been driven by growing demand from our clients. In the past 5 years, Sundia has successfully established collaborations with over 85 client companies in North America, Europe, and Japan.

For Sundia, our professional leadership is an important asset. Our management team is made up of scientists with advanced degrees or training and who have extensive working/management experience in North America. Our team has rich experience in organic synthesis, medicinal chemistry, process chemistry, biology, business management, and law. Our research team comprises over 600 scientists, among which 90% have a Ph.D. or a MS; and 10% a BS.